Optimising experimental design for high-throughput phenotyping in mice: a case study.
To further the functional annotation of the mammalian genome, the Sanger Mouse Genetics Programme aims to generate and characterise knockout mice in a high-throughput manner. Annually, approximately 200 lines of knockout mice will be characterised using a standardised battery of phenotyping tests covering key disease indications ranging from obesity to sensory acuity. From these findings secondary centres will select putative mutants of interest for more in-depth, confirmatory experiments. Optimising experimental design and data analysis is essential to maximise output using the resources with greatest efficiency, thereby attaining our biological objective of understanding the role of genes in normal development and disease. This study uses the example of the noninvasive blood pressure test to demonstrate how statistical investigation is important for generating meaningful, reliable results and assessing the design for the defined research objectives. The analysis adjusts for the multiple-testing problem by applying the false discovery rate, which controls the number of false calls within those highlighted as significant. A variance analysis finds that the variation between mice dominates this assay. These variance measures were used to examine the interplay between days, readings, and number of mice on power, the ability to detect change. If an experiment is underpowered, we cannot conclude whether failure to detect a biological difference arises from low power or lack of a distinct phenotype, hence the mice are subjected to testing without gain. Consequently, in confirmatory studies, a power analysis along with the 3Rs can provide justification to increase the number of mice used.
Karp
Natasha A
NA
Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Baker
Lauren A
LA
Gerdin
Anna-Karin B
AK
Adams
Niels C
NC
Ramírez-Solis
Ramiro
R
White
Jacqueline K
JK
D000704:Analysis of Variance; D000818:Animals; D001794:Blood Pressure; D001795:Blood Pressure Determination / Q000379:methods*; D003627:Data Interpretation, Statistical; D005188:False Negative Reactions; D005189:False Positive Reactions; D006339:Heart Rate; D057166:High-Throughput Screening Assays / Q000379:methods*; D051379:Mice; D018345:Mice, Knockout; D010641:Phenotype; D015203:Reproducibility of Results; D012107:Research Design
Drug Discov Today. 2002 Jun 1;7(11):S55-63
12047881
Exp Gerontol. 1997 Jan-Apr;32(1-2):39-47
9088900
PLoS One. 2009 Nov 30;4(11):e7824
19956596
Am J Hypertens. 2008 Dec;21(12):1288-91
18846043
Naturwissenschaften. 2007 May;94(5):401-6
17216184
Lab Anim. 1994 Jul;28(3):212-21
7967459
Trends Pharmacol Sci. 2003 Jul;24(7):341-5
12871666
Nat Methods. 2009 Jul;6(7):493-5
19525957
Hypertension. 2005 Feb;45(2):299-310
15611363
Nat Rev Drug Discov. 2003 Jan;2(1):38-51
12509758
Genome Biol. 2003;4(4):210
12702200
PLoS Genet. 2006 Aug 25;2(8):e118
16933996
Mol Cell Biol. 2008 Apr;28(8):2590-7
18268011
Cell. 2007 Jan 12;128(1):9-13
17218247
Psychol Methods. 2001 Dec;6(4):387-401
11778679
ILAR J. 2002;43(4):214-22
12391397
Life Sci. 2008 Sep 26;83(13-14):502-10
18761356
Genomics. 2005 Oct;86(4):495-503
16054333
Dis Model Mech. 2008 Sep-Oct;1(2-3):109-12
19048073
Psychol Methods. 2000 Jun;5(2):199-213
10937329
Mamm Genome. 2007 Jul;18(6-7):412-24
17514509
Hypertension. 1995 May;25(5):1111-5
7737724
Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2408-15
14962829
Gene. 2001 Jul 25;273(1):29-39
11483358